| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
HAMBURG, Germany—Evotec AG and Sanofi have begun exclusive negotiations for a major multi-component strategic alliance that could run over the next five years. The collaboration will consist of three major strategic initiatives focused on improving innovation effectiveness in the drug discovery and preclinical development space. Evotec also expects this undertaking to bolster its position as “the leading drug discovery collaboration partner to the pharma and biotech industry as well as academia.”
 
This collaboration will entail a minimum guaranteed commitment from Sanofi to Evotec of €250 million (approximately $309.5 million) over the next five years, including an upfront cash payment to be defined in the agreement. The initiative will also include a co-development agreement with associated upfront, development, regulatory and sales milestones, in addition to royalties that will benefit both parties. This deal is expected to be signed in the first half of next year, subject to finalization of the definitive agreements and completion of the appropriate social process.
 
"Open innovation is a key driver of Sanofi's strategy. We believe Evotec will be an ideal partner, a company that fits our quality expectations and our strategic vision. Our collaboration will secure the future for our employees in Toulouse and importantly accelerate our pipeline productivity," Dr. Elias Zerhouni, president of Global R&D for Sanofi, commented in a statement.
 
Within the three strategic initiatives, one will consist of pipeline-building, in which Sanofi and Evotec will collaborate on selected preclinical development projects with a focus on oncology and potential Cure X/Target X initiatives. Typically, that will feature Evotec accelerating projects to the point of clinical development candidates, at which point Sanofi may take over development and commercialization. Evotec will license a portfolio of projects from Sanofi, including five preclinical projects in oncology that the companies will jointly progress to IND-stage before potential partnering.
 
Additionally, Evotec will continue expanding its Cure X/Target X business model, an initiative that Sanofi will fund through a commitment to Evotec's scouting strategy over the course of the agreements. Sanofi could also provide support for individual projects that progress through this program.
 
Evotec will also expand its capabilities by acquiring Sanofi's drug discovery operations in Toulouse, a small-molecule discovery site with more than 200 scientists. Evotec's expanded capabilities will cover the early-stage discovery and preclinical process from screening to medicinal chemistry.
 
In conjunction with these initiatives, the companies will be combining their libraries to make them available for screening to Evotec's partners. Sanofi's library, established on its Toulouse site, has over one million compounds, greatly boosting Evotec's library of more than 400,000 compounds. Evotec will screen the libraries against collaborators' and partners' targets under pre-agreed upon terms, from which Sanofi will receive a contribution if a product is developed from a library hit.

"We are very proud that Sanofi has chosen Evotec for this significant alliance,” Dr. Werner Lanthaler, CEO of Evotec, said in a press release. “This collaboration is a major milestone in the drug discovery space and accelerates Evotec's strategy to become the leading drug discovery partner to the Pharma and biotech industry as well as academia. We will warmly welcome the Sanofi employees to the Evotec Group and look forward to working with them."


SOURCE: Evotec AG press release

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue